VS-6766 + Abemaciclib + Fulvestrant
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Trial Timeline
Feb 23, 2023 → Dec 31, 2028
NCT ID
NCT05608252About VS-6766 + Abemaciclib + Fulvestrant
VS-6766 + Abemaciclib + Fulvestrant is a phase 1/2 stage product being developed by Eli Lilly for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05608252. Target conditions include Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05608252 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Breast Cancer